Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
209,67 $
+0,68 $
+0,33%
177,82 € 20:22:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,05%
Nachhaltigkeits-Score
54 %
Index-Zuordnung
S&P 500
Weiter aufwärts? Long handeln - Jetzt mit Hebel 24,68: MM1NAR
Werbung

AbbVie News

30.06.25 - PR Newswire
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
AbbVie to Host Second-​Quarter 2025 Earnings Conference Call PR Newswire
29.06.25 wallstreetONLINE Redaktion
Dividenden im Fokus: Fünf Dividenden-Favoriten für das zweite Halbjahr
Wegen geopolitischer Risiken bleiben solide Dividendenaktien weiter gefragt. Laut CNBC Pro bieten diese fünf Favoriten stabile Erträge, Analystenvertrauen und teils ein ...
22.06.25 wallstreetONLINE Redaktion
Blockbuster-Kandidaten: 14 Aktien & 2 ETFs mit Milliardenpotenzial, die wie Bill Gates Alzheimer angehen
Viele forschende Pharmaunternehmen arbeiten intensiv an neuen Alzheimer-​Mitteln, die in den kommenden Jahren auf den Markt kommen könnten. Dies sind die ...
20.06.25 - PR Newswire
AbbVie Declares Quarterly Dividend
AbbVie Declares Quarterly Dividend PR Newswire
18.06.25 - PR Newswire
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-​to-Head Study Compared to ...
16.06.25 - PR Newswire
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-​Risk Myelodysplastic Syndromes PR Newswire
11.06.25 - PR Newswire
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus PR Newswire
03.06.25 - PR Newswire
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals PR Newswire
03.06.25 - PR Newswire
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference PR Newswire
30.05.25 - PR Newswire
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" PR Newswire
30.05.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire
29.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
27.05.25 - PR Newswire
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
AbbVie Features New Data Across Difficult-​to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio PR Newswire
22.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
16.05.25 - PR Newswire
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV PR Newswire
14.05.25 - PR Newswire
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-​tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression ...
14.05.25 - PR Newswire
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-​Generation siRNA Therapies Across Multiple Therapeutic Areas PR ...
13.05.25 - PR Newswire
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV PR Newswire
12.05.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders PR Newswire
09.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire

Newssuche

Videos

newspaper
16.04.26 +3,07%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »